Bortezomib in Treating Patients With Myelodysplastic Syndromes

Completed · Phase 2

Conditions studied: Myelodysplastic Syndromes

In brief

RATIONALE: Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase II trial is studying how well bortezomib works in treating patients with myelodysplastic syndromes.

Key facts

Study ID

NCT00262873

Run by

University of Rochester

People needed

8

Starts

2005-05-01

Expected to finish

2010-10-01

Last updated by the study team

2016-05-09

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• James P. Wilmot Cancer Center at University of Rochester Medical Center — Rochester, New York, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.